The causes and mechanisms of acute myeloid leukemia come down to one process: a blood-forming cell in the bone marrow picks up a series of genetic changes that let it multiply without maturing. In most people these mutations are acquired by chance, especially with age. Known risk factors include previous chemotherapy or radiation, benzene exposure, smoking, some inherited conditions, and earlier blood disorders such as myelodysplastic syndromes. The result is a marrow packed with immature blasts that crowd out healthy blood production.
What Is Acute Myeloid Leukemia?
Acute myeloid leukemia (AML) is a fast-growing cancer of the myeloid cell line, the family of cells that normally becomes red cells, platelets, and several types of white blood cells, such as neutrophils and monocytes. It is one of many hematologic disorders, and it is the most common acute leukemia in adults.
“Acute” means the disease progresses over weeks rather than years, and it needs prompt treatment. AML becomes more common with age, and most patients are older adults.
Mechanisms: How AML Develops
Normal hematopoiesis is tightly controlled. Stem cells in the bone marrow divide, and their offspring mature step by step into functioning blood cells. AML breaks this system in two main ways.
A Block in Maturation
Mutations in genes that control differentiation, such as the transcription factors RUNX1 and CEBPA, freeze cells at an immature stage. These blasts cannot become working neutrophils, red cells, or platelets.
Uncontrolled Growth and Survival
Other mutations switch on growth signaling. FLT3 mutations, for example, keep a growth receptor permanently active. Changes that help cells avoid normal cell death, including reliance on the survival protein BCL-2, let the clone persist.
Clonal Evolution
AML rarely arises from a single mutation. An early “founder” change, often in an epigenetic regulator such as DNMT3A, TET2, or IDH1/IDH2, creates a slightly abnormal clone. Later mutations, such as in NPM1 or FLT3, then tip it into full leukemia. Some older adults carry small mutated clones for years without disease, a state called clonal hematopoiesis.
As blasts accumulate, they take up space and resources in the marrow, causing bone marrow failure and a range of hematological problems: anemia, low platelets, and too few functioning neutrophils.
Key Genetic Changes in AML
Genetic testing is part of every AML diagnosis because the specific abnormality affects both prognosis and treatment choices.
| Genetic change | What it does | Clinical relevance |
|---|---|---|
| t(15;17), PML-RARA | Blocks maturation at the promyelocyte stage | Defines acute promyelocytic leukemia; treated with ATRA and arsenic trioxide |
| t(8;21) and inv(16) | Disrupt core binding factor, a key differentiation regulator | Generally favorable with chemotherapy |
| NPM1 mutation | Mislocates a protein involved in cell growth control | Often favorable when FLT3-ITD is absent or low |
| FLT3 mutation | Keeps a growth-signaling receptor switched on | Higher relapse risk; FLT3 inhibitors available |
| IDH1 / IDH2 mutation | Produces a metabolite that disrupts epigenetic control | IDH inhibitors available |
| TP53 mutation, complex karyotype | Loss of genome protection | Adverse prognosis |
Causes and Risk Factors
In most cases there is no identifiable trigger. Mutations accumulate as cells divide over a lifetime, which is why age is the single biggest risk factor. Recognized contributors include:
Treatment-Related AML
Previous chemotherapy, particularly alkylating agents and topoisomerase II inhibitors, and radiation therapy for another cancer can cause therapy-related AML. It tends to appear several years after treatment and often carries adverse genetic changes.
Environmental and Lifestyle Exposures
- Benzene: a well-established cause, found in some industrial settings and in tobacco smoke
- Smoking: an established lifestyle risk factor for AML
- High-dose ionizing radiation: for example, from nuclear accidents or atomic bomb exposure
Pre-Existing Blood Disorders
Myelodysplastic syndromes and myeloproliferative neoplasms can progress to AML. This is called secondary AML.
Inherited Conditions
Down syndrome, Fanconi anemia, and rare familial syndromes involving genes such as RUNX1, CEBPA, and DDX41 increase risk. Inherited forms are uncommon but important, because relatives may be affected and may be considered as stem cell donors.
What Does Not Cause AML
Patients often ask whether stress, a past injury, diet, or an ordinary infection caused their leukemia. None of these is an established cause. Everyday exposures such as mobile phones and routine medical X-rays are not recognized risk factors either, and AML is not the result of anything a patient did or failed to do.
In my practice I spend time on this point, because guilt is common and unfounded. The honest answer for most people is that AML reflects random genetic errors that build up in dividing cells, and that nobody could have predicted or prevented them.
Symptoms and Diagnosis
Symptoms reflect marrow failure: fatigue and pallor from anemia, bruising and bleeding from low platelets, and fever or infections from too few neutrophils. Some patients have gum swelling or skin lesions from leukemic infiltration.
Diagnosis starts with a blood count and smear, then a bone marrow biopsy. For most subtypes, AML is diagnosed when blasts make up 20% or more of cells in the marrow or blood; certain defining genetic changes allow diagnosis at lower blast counts. Flow cytometry confirms the myeloid lineage, and cytogenetic and molecular tests identify the mutations above.
How Understanding the Mechanisms Shapes Treatment
Induction chemotherapy, classically the “7+3” regimen of cytarabine and an anthracycline, aims to clear blasts and achieve remission. Knowing the mechanism has added targeted options:
- FLT3 inhibitors for FLT3-mutated AML
- IDH1 and IDH2 inhibitors for IDH-mutated AML
- The BCL-2 inhibitor venetoclax, often combined with lower-intensity therapy for older or less fit patients
- ATRA and arsenic trioxide, which force leukemic promyelocytes to mature in acute promyelocytic leukemia
Allogeneic stem cell transplant remains a key curative option for eligible patients with higher-risk disease.
Key Takeaways
- AML results from acquired mutations that block maturation and drive uncontrolled growth of myeloid cells.
- Most cases have no identifiable cause; age is the strongest risk factor.
- Prior chemotherapy or radiation, benzene, smoking, earlier marrow disorders, and some inherited syndromes raise risk.
- Genetic profiling guides prognosis and targeted treatment.
Frequently Asked Questions
Is AML inherited?
Usually not. The mutations in most AML are acquired during life and are not passed on. A small number of families carry inherited predisposition genes, and genetic counseling is offered when the history suggests this.
Could I have prevented my AML?
In most cases, no. The majority of AML arises from random mutations with no avoidable trigger. Not smoking and limiting benzene exposure reduce risk, but they do not guarantee protection.
Is AML contagious?
No. AML cannot be caught from another person, and it is not caused by an infection.
How is AML different from chronic myeloid leukemia?
In AML, cells are stuck at an immature blast stage and the disease moves quickly. In chronic myeloid leukemia, cells still mature, the disease progresses slowly, and it is driven by the BCR-ABL1 fusion gene. Learn more in our leukemia guide.
